J. A. Ware

726 total citations
23 papers, 599 citations indexed

About

J. A. Ware is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, J. A. Ware has authored 23 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in J. A. Ware's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Treatment and Pharmacology (6 papers). J. A. Ware is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Treatment and Pharmacology (6 papers). J. A. Ware collaborates with scholars based in United States, France and Sweden. J. A. Ware's co-authors include Mark J. Dresser, Scott N. Holden, Nageshwar Budha, Leslie Z. Benet, Adam Frymoyer, Kathryn Mazina, Johann S. de Bono, Mika K. Derynck, Amy J. Wagner and Saoirse Dolly and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

J. A. Ware

22 papers receiving 577 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. A. Ware United States	10	317	218	215	130	85	23	599
Rajendra Pradhan United States	14	200 0.6×	131 0.6×	121 0.6×	105 0.8×	91 1.1×	33	795
Melissa O’Gorman United States	15	256 0.8×	220 1.0×	229 1.1×	87 0.7×	17 0.2×	40	613
Kristell Marzin Germany	11	169 0.5×	196 0.9×	312 1.5×	41 0.3×	47 0.6×	18	545
Seng Chuan Tang Netherlands	12	244 0.8×	380 1.7×	148 0.7×	71 0.5×	30 0.4×	15	582
A.E.C. Korst Belgium	16	292 0.9×	264 1.2×	158 0.7×	38 0.3×	61 0.7×	20	681
Stefanie L. Groenland Netherlands	15	184 0.6×	328 1.5×	293 1.4×	197 1.5×	23 0.3×	40	721
James Jiao United States	13	144 0.5×	74 0.3×	139 0.6×	100 0.8×	58 0.7×	18	628
Weiguo Su China	15	225 0.7×	357 1.6×	335 1.6×	69 0.5×	114 1.3×	65	699
Noelia Nebot United States	11	180 0.6×	164 0.8×	62 0.3×	94 0.7×	34 0.4×	17	432
Stéphanie van Hoppe Netherlands	12	148 0.5×	257 1.2×	73 0.3×	91 0.7×	42 0.5×	15	449

Countries citing papers authored by J. A. Ware

Since Specialization

Citations

This map shows the geographic impact of J. A. Ware's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Ware with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Ware more than expected).

Fields of papers citing papers by J. A. Ware

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. Ware. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Ware. The network helps show where J. A. Ware may publish in the future.

Co-authorship network of co-authors of J. A. Ware

This figure shows the co-authorship network connecting the top 25 collaborators of J. A. Ware. A scholar is included among the top collaborators of J. A. Ware based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. A. Ware. J. A. Ware is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ware, J. A., et al.. (2024). Dehydrogenation of formic acid by first-row transition-metal/crown ether complexes studied by mass spectrometry and theoretical calculations. International Journal of Mass Spectrometry. 508. 117391–117391.

Shi, Yifan, et al.. (2016). Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 126. 117–123. 5 indexed citations

Shimizu, Hisao, et al.. (2014). A supported liquid extraction-LC–MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 100. 150–156. 6 indexed citations

Calvo, Emiliano, Valentina Boni, Rebecca S. Heist, et al.. (2014). Phase 1B Study of Oral Dual-Pi3K/Mtor Inhibitor Gdc-0980 in Combination with Carboplatin (Carbo)/Paclitaxel (Pac) ± Bevacizumab (Bev) and Cisplatin (Cis)/Pemetrexed (Pem) in Patients (Pts) with Advanced Solid Tumors and Nsclc. Annals of Oncology. 25. iv429–iv429. 6 indexed citations

Budha, Nageshwar, Adam Frymoyer, Mark J. Dresser, et al.. (2012). Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?. Clinical Pharmacology & Therapeutics. 92(2). 203–213. 271 indexed citations

Moreno, Víctor, Richard D. Baird, Kinjal Shah, et al.. (2011). A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.. Journal of Clinical Oncology. 29(15_suppl). 3021–3021. 33 indexed citations

Morrison, Glenn, Brian Dean, Cornelis E. C. A. Hop, et al.. (2011). A solid phase extraction-liquid chromatographic–tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development. Journal of Pharmaceutical and Biomedical Analysis. 61. 1–7. 9 indexed citations

Groen, Harry J.M., Alex A. Adjei, Grace K. Dy, et al.. (2011). 9012 POSTER DISCUSSION A Phase lb Study to Evaluate the PI3-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC). European Journal of Cancer. 47. S595–S595. 1 indexed citations

Wagner, Amy J., Johanna C. Bendell, Saoirse Dolly, et al.. (2011). A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3020–3020. 60 indexed citations

10.

Besse, Benjamin, Jean‐Charles Soria, Carlos Gomez‐Roca, et al.. (2011). A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 3044–3044. 18 indexed citations

11.

Krop, IE, Antonio C. Wolff, EP Winer, et al.. (2010). Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer. Cancer Research. 70(24_Supplement). P6–15. 8 indexed citations

12.

Dolly, Saoirse, Amy J. Wagner, J. C. Bendell, et al.. (2010). A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 28(15_suppl). 3079–3079. 21 indexed citations

13.

Wagner, Andrew J., Patricia LoRusso, Raoul Tibes, et al.. (2009). A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3501–3501. 53 indexed citations

14.

Sarker, Debashis, Rebecca Kristeleit, Kathryn Mazina, et al.. (2009). A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. Journal of Clinical Oncology. 27(15_suppl). 3538–3538. 34 indexed citations

15.

Hoff, Daniel D. Von, Amy J. Wagner, P. LoRusso, et al.. (2009). 1205 A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours. European Journal of Cancer Supplements. 7(2). 122–122. 7 indexed citations

16.

Sarker, Debashis, Martin Förster, Martijn P. Lolkema, et al.. (2009). 1204 A Phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. European Journal of Cancer Supplements. 7(2). 121–121. 5 indexed citations

17.

Ware, J. A., et al.. (1995). Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.. Drug Metabolism and Disposition. 23(2). 295–297. 3 indexed citations

18.

Ware, J. A.. (1990). Introduction: Section 2. Clinical Drug Investigation. 2(S5). 24–24. 1 indexed citations

19.

Rubio-Terrés, Carlos, et al.. (1989). Effect of indomethacin in autotransplanted colonic tumors. Diseases of the Colon & Rectum. 32(6). 488–491. 16 indexed citations

20.

Larsson, Mats & J. A. Ware. (1983). Effects of Isotonic Fluid Load on Plasma Water and Extracellular Fluid Volumes in the Rat. European Surgical Research. 15(5). 262–267. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact